ReviewAntibiotics (Basel, Switzerland)2020
Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 168 citations in OpenAlex.
- Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.Antimicrobial agents and chemotherapy · 2026Trial
- Beneficial Effect of Olive Leaf Extract as an Adjunct to Standard Antifungal Therapy in TreatingInternational journal of molecular sciences · 2025Trial
- Treatment recommendations for recurrent vulvovaginal candidiasis across complementary and conventional disciplines: a national survey of Australian healthcare professionals.International journal of clinical pharmacy · 2026Article
- Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistantmSphere · 2026Article
- Effect of tranexamic acid on planktonic and biofilm susceptibility of Candida albicans.BMC microbiology · 2026Article
- Burden of non-invasive fungal infections and antifungal therapy in pediatric primary care settings: FUNGICARE Project.Italian journal of pediatrics · 2026Article
- Article
- Sensitive and eco-friendly extraction of antifungal drugs from artificial urine and saliva samples using MSPE coupled with HPLC-DAD.RSC advances · 2026Article
- The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat.The Journal of antimicrobial chemotherapy · 2026Article
- In Vitro Modeling of Mycelium Biomass Growth Kinetics of the Novel Fungicolous SpeciesJournal of fungi (Basel, Switzerland) · 2026Article
- Butyrolactol A enhances caspofungin efficacy via flippase inhibition in drug-resistant fungi.Cell · 2026Article
- Emerging Applications of Triazole Antifungal Drugs.International journal of molecular sciences · 2026Review
- Integrative Transcriptomic and Systems Biology Analyses IdentifyMicroorganisms · 2026Article
- Solvent dependent bioactivity and spectroscopic characterization of neovestitol from Nigerian propolis using experimental and computational methods.Scientific reports · 2026Article
- Novel Drug Delivery Systems for the Management of Vulvovaginal Candidiasis: Enhancing Therapeutic Efficacy.Current pharmaceutical design · 2026Review
- Bioactive Constituents ofDrug design, development and therapy · 2026Review
- Development and In Vivo Evaluation of QbD-Assisted Squalene-based Luliconazole Entrapped Ethosomal Gel for the Skin Fungal Infection.AAPS PharmSciTech · 2025Article
- Predicting the Structural Effects of CUG Codon Translation on Uncharacterized Proteins inJournal of fungi (Basel, Switzerland) · 2025Article
- Butyrolactol A potentiates caspofungin efficacy against resistant fungi via phospholipid flippase inhibition.bioRxiv : the preprint server for biology · 2025Article
- Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Fungal infections represent an increasing threat to a growing number of immune- and medically compromised patients. Fungi are eukaryotic organisms and, as such, there is a limited number of selective targets that can be exploited for antifungal drug development. This has also resulted in a very restricted number of antifungal drugs that are clinically available for the treatment of invasive fungal infections at the present time-polyenes, azoles, echinocandins, and flucytosine. Moreover, the utility of available antifungals is limited by toxicity, drug interactions and the emergence of resistance, which contribute to high morbidity and mortality rates. This review will present a brief summary on the landscape of current antifungals and those at different stages of clinical development. We will also briefly touch upon potential new targets and opportunities for novel antifungal strategies to combat the threat of fungal infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.